Sarcopenic phenotype and functional status of skeletal muscles in rheumatoid arthritis patients with biological therapy

Aim. To evaluate skeletal muscle mass, muscle strength and physical performance in rheumatoid arthritis (RA) women with biological therapy.

Materials and methods. The study included 63 women (average age 60.3 ± 8.9 years) with confirmed RA treated with biological therapy and 117 age-matched RA patients who had never previously treated with biological therapy. Clinical and laboratory examination, evaluation of body composition using dual-energy X-ray densitometry and tests to assess muscle strength and physical performance were carried out.

Results. The frequency of sarcopenic phenotype among RA patients was 23.3 %: in those who received biological medication – 27.0 %, in the control – 21.4 % (p > 0.05). There were no differences between the groups based on the results of muscle strength assessment tests, however, patients on biological therapy performed significantly better the short physical performance battery (SPPB) and had a higher walking speed (p = 0.016 and p = 0.002, respectively). Univariate linear regression analysis confirmed the relationship of the presence of biological therapy with the functional status of the muscles according to the results of SPPB (b* = 0.24; p = 0.018) and walking speed (b* = 0.28; p = 0.006).

Conclusion. The frequency of sarcopenic phenotype among patients with RA was 23.3 % and was comparable in those who received biological therapy and without it. There were no differences in muscle strength depending on the presence of biological therapy, but the functional status of skeletal muscles was significantly better in women who received such treatment.

1. Rall L.C., Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford) 2004;43(10):1219–23. DOI: 10.1093/rheumatology/keh321

2. Cruz-Jentoft A.J., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(4):601. DOI: 10.1093/ageing/afz046

3. Dietzel R., Wiegmann S., Borucki D. et al. Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. RMD Open 2022;8(2):e002600. DOI: 10.1136/rmdopen-2022-002600

4. Myasoedova S.E., Rubtsova О.А., Myasoedova Е.Е. Body composition and bone mineral density in women with rheumatoid arthritis. Klinitsist = The Clinician 2016;10(3):41–5. DOI: 10.17650/1818-8338-2016-10-3-41-45 (In Russ.)

5. Torii M., Hashimoto M., Hanai A. et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol 2019;29(4):589–95. DOI: 10.1080/14397595.2018.1510565

6. Ngeuleu A., Allali F., Medrare L. et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int 2017;37(6):1015–20. DOI: 10.1007/s00296-017-3665-x

7. Mochizuki T., Yano K., Ikari K., Okazaki K. Sarcopenia-associated factors in Japanese patients with rheumatoid arthritis: A crosssectional study. Geriatr Gerontol Int 2019;19(9):907–12. DOI: 10.1111/ggi.13747

8. Hasegawa E., Ito S., Kurosawa Y. et al. The efficacy of biological disease-modifying antirheumatic drugs on sarcopenia in patients with rheumatoid arthritis. Intern Med 2023;62(3):373–9. DOI: 10.2169/internalmedicine.9600-22

9. Santo R.C., Silva J.M., Lora P.S. et al. Cachexia in patients with rheumatoid arthritis: A cohort study. Clin Rheumatol 2020;39(12):3603–13. DOI: 10.1007/s10067-020-05119-y

10. Vial G., Lambert C., Pereira B. et al. The effect of TNF and nonTNF-targeted biologics on body composition in rheumatoid arthritis. J Clin Med 2021;10(3):487. DOI: 10.3390/jcm10030487

11. Engvall I.L., Tengstrand B., Brismar K., Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010;12(5):R197. DOI: 10.1186/ar3169

12. Tournadre A., Pereira B., Dutheil F. et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle 2017;8(4):639–46. DOI: 10.1002/jcsm.12189

13. Toussirot E., Marotte H., Mulleman D. et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. Arthritis Res Ther 2020;22(1):224. DOI: 10.1186/s13075-020-02297-7

14. Al Khayyat S.G., Falsetti P., Conticini E. et al. Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study. Reumatologia 2021;59(4):206–10. DOI: 10.5114/reum.2021.108430

15. Toroptsova N.V., Dobrovolskaya O.V., Efremova A.O., Nikitinskaya O.A. Diagnostic value of the SARC-f questionnaire and muscle strength tests for the detection of sarcopenia in patients with rheumatoid arthritis. Nauchcno-Practicheskaya Revmatologia = Rheumatology Science and Practice 2020;58(6):678–82. DOI: 10.47360/1995-4484-2020-678-82 (In Russ.)